New combo therapy aims to deepen remissions in Hard-to-Treat myeloma

This study tests whether adding the drug selinexor to standard bispecific antibody therapy can help people with relapsed or refractory multiple myeloma achieve deeper remissions. About 27 adults who have already tried at least 4 prior treatments will take selinexor alongside their antibody therapy for up to 12 months. The main goals are to check safety and to see if the combination can make cancer undetectable by a sensitive test (MRD negativity) at 12 months.